@Article{chd.12432,
AUTHOR = {Delaram Molkara, Jose A. Silva Sepulveda, Thomas Do, Christopher Davis, Gregory P. Goldstein, John W. Moore, Howaida G El-Said},
TITLE = {Tissue plasminogen activator for neonatal coronary thrombosis presenting with mitral valve regurgitation and impaired ventricular function},
JOURNAL = {Structural and Congenital Heart Disease},
VOLUME = {12},
YEAR = {2017},
NUMBER = {3},
PAGES = {270--274},
URL = {http://www.techscience.com/schd/v12n3/39109},
ISSN = {3071-1738},
ABSTRACT = {<b>Objective:</b> Neonatal coronary thrombosis is a rarely reported disorder, with variable outcomes
described. This study assessed the feasibility and safety of an institutional protocol using tissue
plasminogen activator (tPA) administration for the treatment of neonatal coronary artery thrombi.<br/>
<b>Methods:</b> They reviewed the outcome of three neonates with clinical evidence of myocardial
infarction secondary to coronary thrombosis. All three underwent the tPA treatment protocol.<br/>
<b>Results:</b> The three described cases presented at 5 hours, 15 hours, and 10 days of life. The
patients identified underwent the tPA protocol at least once. There was clinical evidence of
improvement in coronary flow, as well as demonstration of increased left ventricular function and
decreased mitral regurgitation. No major adverse events occurred.<br/>
<b>Conclusion:</b> Thrombolytic therapy with this tPA protocol may be safe and effective in treating
neonates with coronary thrombosis.},
DOI = {10.1111/chd.12432}
}